RGNX
REGENXBIO Inc.
NasdaqGS Healthcare United States
7,76 $US
+4.44% today
-42.82% YTD · -27.41% 1Y
5
Insider transactions
SEC Form 4 · AMF · BaFin — rolling 90 days
17
Hedge funds tracked
Latest available SEC 13F filings
65
/ 100
STRONG

Analysis REGENXBIO Inc. (RGNX) — Kairos Score 65/100

Composite score aggregating 8 smart money dimensions: insiders (SEC/AMF/BaFin), hedge funds, politicians & gurus, price momentum, valuation, analyst consensus, financial health, earnings momentum. The higher the score, the more favorable the institutional signals consensus.

💡 Detailed breakdown (the 8 sub-scores) available in the Premium dashboard.

About REGENXBIO Inc.

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Key info

👔
CEO
Mr. Curran M. Simpson M.S.
📍
HQ
9804 Medical Center Drive, Rockville, MD, 20850, United States
👥
Employees
371
💰
Market cap
513 582 700,00 $US
💸
Dividend yield
—

🕴️ Insider activity (90 days)

5 transactions — 2 buys and 0 sales reported by REGENXBIO Inc. executives.

MC
Malzahn Craig
Chief Technology Officer · 2026-09-01
Other
CM
Chan Mitchell
Chief Financial Officer · 2026-09-01
Other
CG
Ciongoli Gregory Austin
2026-08-27
Buy

🏦 Hedge Funds

17 institutional funds report a position on RGNX in their latest SEC quarterly filing.

BlackRock, Inc.
VANGUARD GROUP INC
STATE STREET CORP
JPMORGAN CHASE & CO
VANGUARD CAPITAL MANAGEMENT LLC

📰 Recent news

15 recent articles on RGNX.

🧠 What makes Kairos Insider

Beyond raw data, we aggregate and score every smart money signal to give you a unique view.

🧠

Kairos Score 0-100

8-dimension composite score: insiders · hedge funds · politicians · momentum · valuation · health · analysts · earnings.

🎯

Insider Clusters

Detection of clustered purchases or sales by several executives in the same stock.

🏦

13F Hedge Funds

Berkshire, Pershing Square, Tiger Global, Bridgewater and other reporting funds.

📈

ETF Rotations

NANC & GOP (Pelosi & Republicans), GURU (top hedge funds), ARK (Cathie Wood). See who enters and exits each week.

🔥

Google Trends

Spot marked changes in search interest around the stocks being followed.

📧

Email alerts

Create your watchlist and receive a brief of events affecting your tickers.

Companies in the same sector as REGENXBIO Inc.

Official sources · Public data · SEC EDGAR — Form 4 & 13F · AMF — Executive filings · BaFin — Directors' Dealings · Yahoo Finance · Alpha Vantage

🔓 Unlock the full analysis

This public page only shows a preview. The full analysis of RGNX on the Kairos Insider dashboard includes:

✅ Full Kairos Score (8-axis radar + synthesis)
✅ History of all 5 insider transactions over 90 days
✅ All 17 detected institutional funds
✅ Thematic ETFs (ARK, BUZZ, NANC, GOP, JEPI…)
✅ Hot Stocks Google Trends
✅ Available history: AUM + rotations
✅ Fundamentals (P/E, PEG, EV/EBITDA, ROE…)
✅ Financial health (Altman Z, Piotroski F)
✅ Sector peers + recent earnings
See full analysis →
Analyze other tickers for free →

Free signup · Pro €19/month or €190/year